Study objective: Two large randomized trials recently demonstrated efficacy of methicillin-resistant Staphylococcus aureus (MRSA)-active antibiotics for drained skin abscesses. We determine whether outcome advantages observed in one trial exist across lesion sizes and among subgroups with and without guideline-recommended antibiotic indications.
INTRODUCTION Background
The primary treatment of an abscess is drainage. 1 Past studies of adjunctive antibiotic treatment, conducted before and after the emergence of community-associated methicillin-resistant Staphylococcus aureus (MRSA), 2 were small and did not clearly demonstrate benefit. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Recently, 2 large, US, randomized, placebo-controlled trials demonstrated that treatment with an antibiotic possessing in vitro activity against MRSA was associated with improved outcomes among patients with a skin abscess that received drainage and who were treated as outpatients. 13, 14 The trial by Daum et al 13 enrolled 786 patients who were assigned 1:1:1 to treatment with clindamycin, trimethoprim-sulfamethoxazole, or placebo, and the trial by Talan et al 14 enrolled 1,265 patients assigned 1:1 to treatment with trimethoprim-sulfamethoxazole or placebo. Talan et al 14 found that significantly fewer antibiotictreated participants required a new antibiotic through 7 to 14 days after treatment, as well as lower rates of subsequent surgical drainage procedures and infection at a new skin site through 42 to 56 days after treatment.
Practice guidelines for abscess treatment issued by the Centers for Disease Control and Prevention and the Infectious Diseases Society of America before these trials stated that drainage is sufficient for many patients.
Editor's Capsule Summary
What is already known on this topic Antibiotics targeting methicillin-resistant Staphylococcus aureus (MRSA) after superficial cutaneous abscess drainage in the emergency department improve outcomes.
What question this study addressed Is the benefit of antibiotics for MRSA abscesses maintained across various clinical subgroups?
What this study adds to our knowledge In a planned subanalysis of 1,057 participants in a randomized trial of placebo versus trimethoprimsulfamethoxazole after incision and drainage, outcomes were improved with antibiotic treatment irrespective of abscess size, fever, previous MRSA, and other common clinical features.
How this is relevant to clinical practice
Trimethoprim-sulfamethoxazole appears to improve cure rates after incision and drainage of MRSA abscesses regardless of patient characteristics. specific associated conditions, including an infected site diameter greater than 5 cm, cellulitis, systemic inflammatory response syndrome, diabetes, and recurrent infection. The 2 recent randomized trials demonstrating antibiotic efficacy included patients with a wide range of abscess cavity and surrounding erythema dimensions, as well as various comorbidities, including diabetes. 13, 14 The extent to which antibiotics are as efficacious for small and uncomplicated abscesses and the relative magnitude of the treatment effect in various subgroups are unclear.
Importance
Between 1993 and 2005, annual emergency department (ED) visits for skin and soft tissue infections in the United States increased from 1.2 to 3.4 million, primarily because of an increased incidence of abscesses. 18, 19 Determining optimal treatment for affected patients is crucial to ensuring rapid recovery without need for further medical interventions and promoting good antibiotic stewardship.
Goals of This Investigation
Our goals were to determine the degree to which outcome advantages observed with adjunctive antibiotics for all participants in the study by Talan et al 14 existed among subgroups with and without conditions for which antibiotics have been selectively recommended and identify patients who most benefit from treatment. Therefore, we conducted a planned subgroup analysis to determine whether, among these subgroups of patients, treatment with a 7-day course of trimethoprim-sulfamethoxazole was associated with higher cure rates than placebo such that no additional antibiotics or drainage procedures were required through 7 to 14 days and 42 to 56 days after treatment.
MATERIALS AND METHODS Study Design and Setting
We conducted a planned subgroup analysis among participants of a multicenter, double-blind, randomized trial demonstrating superiority of trimethoprimsulfamethoxazole to placebo for treatment of patients with a skin abscess receiving incision and drainage and who were treated as outpatients. The trial, full protocol, and statistical analysis plan were previously published. 14 The institutional review board at each site approved the trial.
Selection of Participants
From April 2009 to April 2013, we enrolled patients older than 12 years and presenting to any of 5 US EDs with a cutaneous lesion suspected to be an abscess according to physical examination and ultrasonography or examination alone, and found to have purulent material on surgical exploration. We enrolled only participants with a lesion present for less than 1 week and measuring greater than or equal to 2.0 cm in diameter (ie, from the borders of induration, if fluctuant, or borders of abscess cavity on ultrasonography, if not fluctuant), for whom their treating clinician intended outpatient treatment and who agreed to return for reevaluation and provided written consent.
We excluded patients with the following conditions: indwelling device; suspected osteomyelitis or septic arthritis; diabetic foot, decubitus, or ischemic ulcer; mammalian bite; wound with organic foreign body; infection of another organ system or skin site; perirectal, perineal, or paronychial location; intravenous drug use within previous month, with fever; underlying skin condition; long-term care residence; incarceration; immunodeficiency (eg, absolute neutrophil count <500/ mm 3 , immunosuppressive drugs, active chemotherapy, or known AIDS assessed by subject history); creatinine clearance less than 50 mL/min; cardiac condition with risk of endocarditis; allergy or intolerance to trimethoprimsulfamethoxazole; receiving warfarin, phenytoin, or methotrexate; known glucose-6-phosphate dehydrogenase or folic acid deficiency; pregnant or lactating; trimethoprim-sulfamethoxazole treatment within 24 hours; concurrent treatment with topical or systemic antibiotic; or enrolled in the study within 12 weeks. The treating clinician decided whether any laboratory testing (other than wound cultures) would be conducted.
Interventions
We randomized participants to receive a 7-day course of trimethoprim-sulfamethoxazole (4 single-strength pills, 80 mg/400 mg each, twice daily) or placebo (4 pills twice daily). Clinicians had training in standardized incision and drainage technique. 14 
Methods of Measurement
We collected participant demographic and clinical information, including history of MRSA infection and fever, comorbidities, measured temperature in the ED, and lesion size (Table 1) .
We measured abscess cavity and erythema dimension according to the following methods. After the abscess cavity was opened with a scalpel, the internal cavity was probed with the wooden end of a cotton swab or with an instrument such as a hemostat. This broke up loculations in the abscess and allowed the investigator to estimate the internal dimensions of the abscess cavity by noting how far the probe went to the edge of the abscess cavity from the center. Adding the length of the probe from the center to the edge of the abscess cavity in 4 directions allowed the length and width of the abscess cavity to be measured. The depth of the abscess cavity was determined by measuring the depth to which the probe went to the bottom of the abscess cavity from the outer skin level. Abscesses of some patients enrolled with an abscess size estimated to be greater than or equal to 2 cm were smaller on surgical exploration.
We took all measurements of erythema while the infected area was in a nondependent position (eg, if infection was on the leg, the subject was lying down, not sitting or standing). The border of erythema was marked with a pen. Maximal dimensions of erythema, both width and length, were recorded in centimeters. Investigators attempted to find the infection edge that best distinguished erythematous from nonerythematous skin. Erythema was measured in the dimension of maximal length. The maximal width was measured perpendicular to the axis of the maximal length. The maximal width measurement did not have to be in the center if the erythematous area was irregular.
We sent purulent material from all abscesses for wound culture and susceptibility testing at local laboratories.
Outcome Measures
We defined the primary outcome as the difference in abscess clinical cure rates between patients receiving trimethoprim-sulfamethoxazole and those receiving placebo. We defined clinical cure as resolution of all symptoms and signs of infection, or improvement such that no new antibiotics were prescribed through 7 to 14 days after the end of treatment. In the original trial, primary outcomes were reported in the modified intention-to-treat and per-protocol populations.
14 In both the modified intention-to-treat and per-protocol populations, the clinical cure rate of the trimethoprim-sulfamethoxazole group was significantly higher than that of the placebo group by about the same magnitude (ie, 7 percentage points). Thus, for this subgroup analysis, we evaluated and report outcomes in the perprotocol population (ie, participants who returned for followup and had !75% medication adherence) who could be most accurately assessed for outcomes and treatment effect.
We conducted subgroup analyses for 3 outcomes; clinical cure at 7 to 14 days after the end of treatment, as described above; composite cure, defined as resolution of all symptoms and signs of infection, or improvement such that no additional antibiotics were prescribed or surgical drainage procedures were performed through 7 to 14 days after the end of treatment; and composite cure through 42 to 56 days after the end of treatment.
We evaluated these outcomes among subgroups defined by presence or absence of the following characteristics: abscess cavity maximal dimension greater than or equal to 5 cm; erythema maximal dimension greater than or equal to 5 cm; history of MRSA infection at any time in the past, defined by patient report; fever, defined as history of subjective or measured fever in the preceding week by patient report or measured temperature greater than 38 C (100.4 F) in the ED; diabetes; major comorbidities, defined as relevant serious medical conditions present in greater than 0.5% of the perprotocol population (ie, diabetes, eczema or chronic edema, chronic obstructive pulmonary disease, congestive heart failure, HIV infection, and cancer); and culture positive for MRSA or methicillin-susceptible S aureus. Among this population of ED patients who were thought to be stable for outpatient care, measured temperature greater than 38 C (100. 4 F) was present in less than 1%. Also, few patients were elderly. Therefore, we could not evaluate subgroups with systemic inflammatory response syndrome and advanced age.
Primary Data Analysis
We conducted separate analyses for each characteristic for each of the 3 outcomes described above. We planned secondary assessment of the association of the presence or absence of certain conditions specified by guidelines to determine use of adjunctive antibiotics. As such, we considered all analyses exploratory and unrelated to any specific hypothesis or formal power assessment. Results are presented as point measures of the individual treatment effects (ie, difference in cure rate among participants treated with trimethoprimsulfamethoxazole compared with that of participants treated with placebo) and the associated 95% confidence interval (CI).
The between-group difference in cure rates as a function of maximal abscess and erythema linear dimension is presented. We plotted between-group percentage point differences in cure rates by 1-cm increments of abscess cavity or erythema 20 We excluded participants with missing values from relevant analyses.
RESULTS

Characteristics of Study Subjects
Of 1,265 enrolled patients, 1,247 (98.6%) were randomly assigned to trimethoprim-sulfamethoxazole or placebo and received greater than 1 dose, and 1,057 Figure 1 . Enrollment, randomization, and follow-up of patients with a drained skin abscess treated with trimethoprimsulfamethoxazole or placebo. TMP/SMX, Trimethoprim-sulfamethoxazole; mITT, modified intention-to-treat. CHF, Congestive heart failure; COPD, chronic obstructive pulmonary disease; IV, intravenous; MSSA, methicillin-susceptible S aureus. Participants with missing data were excluded from relevant analyses. *Eight (0.8%) participants were aged 13 to 17 years. † Comorbidities were those present in greater than 0.5%. ‡ A close household contact was defined as someone living in the same household and with similar skin infection in the last month. § Fever was defined as patient report of history of fever in previous week or temperature greater than 38 C (100.4 F) in the ED.
k Largest measurement of length or width was defined as the maximal dimension.
{
Areas of erythema and induration or swelling were calculated with the formula for an ellipse (1/4ÂpÂlengthÂwidth) minus area of probe measurements of length and width of abscess area. # Streptococcal species included group A streptococcus, group B streptococcus, S anginosus, b-hemolytic group C streptococcus, b-hemolytic group F streptococcus, b-hemolytic group G streptococcus, non-group A and B b-hemolytic streptococcus, Viridans group streptococcus, and a-hemolytic streptococcus. **Other isolates included Actinomyces species, Bacteroides species, diphtheroid bacilli, Eikenella corrodens, Enterobacter species, Enterococcus species, Escherichia coli, Fusobacterium species, Haemophilus species, Klebsiella species, Lactobacillus species, Peptostreptococcus species, Porphyromonas species, Prevotella species, Proteus mirabilis, and Veillonella species.
(83.6%) participants qualified for the per-protocol population ( Figure 1 ). Participant characteristics in the per-protocol population are summarized in Table 1 Analysis of the subgroup of participants with and without high-risk conditions for which antibiotics have been recommended for rates of clinical and composite cure through 7 to 14 days and composite cure through 42 to 56 days in the trimethoprim-sulfamethoxazole and placebo groups is shown in Table 2 . For all 3 outcomes, cure rates were higher for participants treated with trimethoprim-sulfamethoxazole than for those treated with placebo in all subgroups (ie, presence or absence of abscess cavity dimension !5 cm, erythema dimension !5 cm, past MRSA infection, fever, diabetes, or a major comorbidity). The magnitude of the difference in cure rates between the trimethoprim-sulfamethoxazole and placebo groups for all 3 outcomes was greater than for the whole population among subgroups with a history of MRSA infection and fever. For example, for composite cure through 42 to 56 days after treatment, the treatment effect for the whole per-protocol population was 12.2 percentage points, whereas it was 22.9 percentage points among participants with a history of MRSA and 16.9 percentage points among those with fever. According to culture results, the greatest treatment effect was associated with lesions that grew MRSA and, to a lesser degree, methicillin-susceptible S aureus, as opposed to other organisms or no growth. No outcome advantage was associated with trimethoprim-sulfamethoxazole among participants with cultures that grew neither MRSA nor methicillin-susceptible S aureus. Figures 2 and 3 show the between-group percentagepoint differences in cure rates among the treatment groups by abscess cavity and erythema maximal dimension, further illustrating that the outcome advantage associated with trimethoprim-sulfamethoxazole existed across all lesion sizes.
LIMITATIONS
This trial has limitations. The original trial was not powered to detect a treatment effect in groups other than in the primary outcome population. A significant treatment effect was generally observed among participants with and without high-risk conditions; however, in a few subgroups, the 95% CI of the difference in cure rates crossed 0, which may have been a result of small subgroup sizes. Furthermore, multiple comparisons were conducted, which leads to a greater likelihood of observing positive associations caused by chance. Analyses were conducted with the per-protocol population for whom follow-up status was available. Although the participant characteristics and magnitude of the treatment effect in the per-protocol and modified intention-to-treat populations were similar, it is possible that the per-protocol population was affected by postrandomization bias. Only patients with a maximal abscess cavity diameter estimated to be greater than or equal to 2 cm according to physical examination or ultrasonography were enrolled. Therefore, our results do not apply to patients with smaller lesions and other conditions that led to ineligibility.
DISCUSSION
Two recent large randomized trials demonstrated the efficacy of adjunctive antibiotics possessing activity against *Overall, for trimethoprim-sulfamethoxazole and placebo groups, clinical cure rate at 7 to 14 days was 92.9% and 85.7% (difference 7.2; 95% CI 3.2 to 11.2), composite cure rate at 7 to 14 days was 86.5% and 74.3% (difference 12.2; 95% CI 7.2 to 17.1), and extended composite cure at 42 to 56 days was 82.4% and 70.2% (difference 12.2; 95% CI 6.8 to 17.6), respectively. Outcomes were defined as follows: clinical cure was defined as resolution of all symptoms and signs of infection, or improvement such that no new antibiotics were prescribed (through 7 to 14 days after the end of treatment); composite cure was defined as resolution of all symptoms and signs of infection, or improvement such that no additional antibiotics or surgical drainage procedures were required (through 7 to 14 days and 42 to 56 days after the end of treatment). † Abscess cavity and erythema dimensions were defined as the maximal dimension (length or width). ‡ Fever was defined as history of fever within the preceding week or temperature greater than 38 C (100.4 F) measured in the ED (0.8%). § Comorbidities were defined as those present in greater than 0.5% of study participants: diabetes (10.9%), eczema or other chronic skin condition (3.4%), chronic obstructive pulmonary disease (1.1%), congestive heart failure (0.9%), HIV infection (1.6%), and cancer (0.9%).
k Culture results were those based on the organism isolated from the primary wound specimen.
MRSA for treatment of patients with a drained skin abscess. 13, 14 This subgroup analysis was planned to test the validity of guidelines for use of adjunctive antibiotics for a drained skin abscess among the largest reported trial population, which mostly consisted of adults.
14 Although exploratory, these results support adjunctive antibiotic treatment for small uncomplicated skin abscesses estimated to be at least 2 cm in diameter by physical examination or ultrasonography. A consistent treatment effect was associated with trimethoprimsulfamethoxazole treatment among patients with small abscess and erythema size and lacking any condition for which antibiotics have been selectively recommended, [15] [16] [17] including history of MRSA infection, fever, diabetes, and other comorbidities. The findings of a treatment effect among participants with an abscess size less than 5 cm and those without diabetes are consistent with the results of the trial by Daum et al, 13 in which pediatric and adult patients with small abscesses of no minimum size were enrolled but those with larger abscesses (ie, >5 cm for adults and >3 to 4 cm for children) and diabetes were excluded. We observed a treatment effect across all dimensions of abscess cavity and associated erythema. Together, the 2 trials suggest that adjunctive antibiotics improve cure rates for a drained uncomplicated skin abscess of any size.
Trimethoprim-sulfamethoxazole is highly active against staphylococci, with 97.4% of study MRSA isolates tested demonstrating in vitro susceptibility. 14 The treatment effect was highly associated with culture of MRSA and, to a lesser degree, methicillin-susceptible S aureus. No treatment effect was found with lesions that grew other organisms or had no growth, a result also found in the trial by Daum et al, 13 supporting the role of antibiotics to treat bacterial tissue infection once an abscess has been drained. Non-S aureus lesions may largely represent inflamed but uninfected cysts, with negative culture results or growth representing skin contamination. Daum et al 13 also found that the cure rate of participants treated with clindamycin was lower among those for whom the staphylococcal isolate demonstrated in vitro resistance as opposed to susceptibility, further supporting this biological model. Specimen Gram's stain or more recently available rapid polymerase chain reaction-based assays of drainage material Overall, for trimethoprim-sulfamethoxazole and placebo groups, clinical cure rate at 7 to 14 days was 92.9% and 85.7% (difference 7.2; 95% CI 3.2 to 11.2), composite cure rate at 7 to 14 days was 86.5% and 74.3% (difference 12.2; 95% CI 7.2 to 17.1), and extended composite cure at 42 to 56 days was 82.4% and 70.2% (difference 12.2; 95% CI 6.8 to 17.6), respectively.*The betweengroup percentage-point differences in cure rates were plotted by 1-cm increments of abscess cavity or erythema dimension. For each increment, cure rates were calculated for those that had the same or smaller-sized lesion. Outcomes were defined as follows: clinical cure was defined as resolution of all symptoms and signs of infection, or improvement such that no new antibiotics were prescribed (through 7 to 14 days after the end of treatment); composite cure was defined as resolution of all symptoms and signs of infection, or improvement such that no additional antibiotics or surgical drainage procedures were required (through 7 to 14 days and 42 to 56 days after the end of treatment).
† Diameter was defined as the maximal linear dimension (length or width) of the abscess cavity, by probe after incision, and erythema, measured on the skin.
to identify staphylococcal infections potentially could guide treatment decisions.
Among all participants, through 42 to 56 days after treatment, recurrent infection at a new site occurred in 19.1% of the placebo group compared with 10.9% of the trimethoprim-sulfamethoxazole group. 14 The composite cure outcome through 42 to 56 days after treatment captured all initial treatment failures and subsequent infections that required either a new antibiotic or drainage procedure. The treatment effect associated with trimethoprimsulfamethoxazole extended through 42 to 56 days in all clinical subgroups. Furthermore, history of MRSA infection and abscesses that grew MRSA were associated with a greater magnitude of treatment benefit compared with that of the entire study population. These observations suggest that trimethoprim-sulfamethoxazole may reduce MRSA colonization for several weeks after initial treatment.
The outcome advantage associated with trimethoprimsulfamethoxazole existed across the range of abscess or erythema dimensions. However, the presence of certain characteristics identified by guidelines [15] [16] [17] as criteria for antibiotic treatment (ie, history of MRSA infection and fever) was associated with the greatest treatment effect. For the entire study population, there was a 12.2-percentage-point higher rate of neither requiring a new antibiotic nor drainage procedure through 42 to 56 days after treatment. This difference was 22.9 percentage points among participants with history of MRSA infection and 16.9 percentage points among those with history of fever in the preceding week or measured elevated temperature in the ED.
Further studies could attempt to validate these subgroup treatment effect associations and further inform shared decisionmaking with patients about benefit, risk, and cost associated with the decision to provide adjunctive antibiotics. However, it may be difficult to accrue a sufficient number of patients in these subgroups. Trimethoprimsulfamethoxazole is off patent, and currently a full course costs approximately $5. Its use was associated with only slightly more mild gastrointestinal adverse effects than placebo, 14 although this antibiotic is rarely associated with serious adverse reactions, such as Stephens-Johnson's syndrome. 21 The trial had inadequate power to detect either an increased rate of rare and serious antibiotic-related adverse effects or a decreased rate of subsequent invasive infections compared with placebo. The study by Daum et al 13 demonstrated efficacy of clindamycin 150 mg 3 times daily and trimethoprim-sulfamethoxazole 160 mg/800 mg twice daily compared with placebo. The trimethoprimsulfamethoxazole dose was half that used in our trial, and Daum et al 13 treated for 10 days, whereas we treated for 7 days. This investigation also found that adverse events were approximately twice as frequent with clindamycin compared with trimethoprim-sulfamethoxazole. Neither trial detected any cases of Clostridium difficile colitis. The costs and risks associated with adjunctive antibiotic treatment must be weighed against those associated with the care and consequences of treatment failure and recurrence.
This subgroup analysis of the largest reported trial comparing antibiotics with placebo for patients with a drained skin abscess found that trimethoprim-sulfamethoxazole treatment was associated with improved outcomes regardless of abscess or erythema size or the presence or absence of conditions for which antibiotics have been selectively recommended, including history of MRSA infection, fever, diabetes, and major comorbidities. The magnitude of the treatment effect was greatest among subgroups with a history of MRSA infection or fever and for those with an abscess caused by MRSA. work; or the acquisition, analysis, or interpretation of data for the work; AND (2) Drafting the work or revising it critically for important intellectual content; AND (3) Final approval of the version to be published; AND (4) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
